1 / 8

Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197. Baseline characteristics of study population of new users and non-users of statins Values are numbers (percentages) unless stated otherwise. Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197.

travis-gentry
Download Presentation

Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

  2. Baseline characteristics of study population of new users and non-users of statinsValues are numbers (percentages) unless stated otherwise Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

  3. Crude incidence per 10 000 person years for study outcomes in both men and women Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

  4. Risk associated with statin type both in men and in women for non-significant and marginal outcomes Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

  5. Risk of significant outcomes associated with type and dose of statin both in men and in women - Part I Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

  6. Risk of significant outcomes associated with type and dose of statin both in men and in women - Part II Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

  7. Relative incidence rate ratios from case series analysis for men and women combined for significant outcomes associated with statin type Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

  8. Numbers needed to harm (NNH) or numbers needed to treat (NNT) and numbers of extra or prevented cases for each outcome over five years in patients aged 35-74 free of cardiovascular disease at baseline with QRISK2 score of ≥20% or ≥15% Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

More Related